Notwithstanding encouraging clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial opposition from managed care entities. These companies are https://janapnbb166897.ampblogs.com/copyright-s-drug-faces-is-encountering-pbm-challenges-the-look-of-reimbursement-fights-78978148